Zhuhai Anbaojian Pharmaceutical Co., Ltd.

The main purpose of the study is to use the clopidogrel bisulfate tablets (trade name: Plavix®, specification: 75 mg) certified by Sanofi (Hangzhou) Pharmaceutical Co., Ltd. as the reference preparation and the clopidogrel bisulfate tablets (specification: 75 mg) developed by Guangdong Quanxin Quanyi Pharmaceutical Co., Ltd. as the test preparation to evaluate the human bioequivalence of the two preparations through a single-center, randomized, open, single-dose, two-sequence, four-cycle, completely repeated crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Main objective: To evaluate the relative bioavailability and bioequivalence of tadalafil tablets provided by Guangdong Quanxin Quanyi Pharmaceutical Co., Ltd. as the test preparation and tadalafil tablets produced by Lilly del Caribe, Inc. as the reference preparation.